These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 11920427)
1. Methotrexate for the treatment of early diffuse scleroderma: comment on the article by Pope et al. Lehman TJ Arthritis Rheum; 2002 Mar; 46(3):845. PubMed ID: 11920427 [No Abstract] [Full Text] [Related]
2. Methotrexate has no antifibrotic effect in bleomycin-induced experimental scleroderma. Ozgen M; Koca SS; Isik A; Ozercan IH J Rheumatol; 2010 Mar; 37(3):678-9. PubMed ID: 20197571 [No Abstract] [Full Text] [Related]
5. Placebo controlled trial of methotrexate in systemic sclerosis. Das SN; Alam MR; Islam N; Rahman MH; Sutradhar SR; Rahman S; Khan GK; Rahim A; Haq SA Mymensingh Med J; 2005 Jan; 14(1):71-4. PubMed ID: 15695960 [TBL] [Abstract][Full Text] [Related]
6. Overlap of systemic sclerosis and rheumatoid arthritis. Alkassab F J Rheumatol; 2007 Jul; 34(7):1593-4. PubMed ID: 17611965 [No Abstract] [Full Text] [Related]
7. Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A or methotrexate: comment on the article by Pasero et al. Alarcón GS Arthritis Rheum; 1997 Apr; 40(4):791-2. PubMed ID: 9125269 [No Abstract] [Full Text] [Related]
8. Why is methotrexate the first selection in disease-modifying antirheumatic drug therapy? Comment on the article by Wolfe et al. Caballero-Uribe CV Arthritis Care Res; 1999 Apr; 12(2):152. PubMed ID: 10513503 [No Abstract] [Full Text] [Related]
9. Effect of folic acid supplementation on the efficacy of methotrexate treatment in rheumatoid arthritis: comment on the article by Khanna et al. Morgan SL; Baggott JE; Alarcón GS Arthritis Rheum; 2006 May; 54(5):1708-9; author reply 1709-10. PubMed ID: 16646062 [No Abstract] [Full Text] [Related]
10. Indirect evidence for the efficacy of methotrexate in diffuse systemic sclerosis. Low AH; Lee P J Rheumatol; 2008 Nov; 35(11):2286. PubMed ID: 19004063 [No Abstract] [Full Text] [Related]
11. Effect of golimumab combined with methotrexate on radiographic progression in rheumatoid arthritis: comment on the article by Emery et al. Graudal N; Jürgens G Arthritis Rheum; 2012 Apr; 64(4):1297-8; author reply 1298-9. PubMed ID: 22231914 [No Abstract] [Full Text] [Related]
12. Unproven hypothesis that leflunomide is better than methotrexate as measured by magnetic resonance imaging: comment on the article by Reece et al. Schnarr S; Hülsemann JL; Zeidler HK Arthritis Rheum; 2003 Jan; 48(1):270-1; author reply 271. PubMed ID: 12528131 [No Abstract] [Full Text] [Related]
13. Treatment of systemic sclerosis. Steen VD Am J Clin Dermatol; 2001; 2(5):315-25. PubMed ID: 11721650 [TBL] [Abstract][Full Text] [Related]
17. Thymoglobulin and cyclophosphamide as treatment for diffuse cutaneous systemic sclerosis. Holmberg LA; Furst DE; McSweeney PA; Nash RA J Rheumatol; 2009 Aug; 36(8):1839. PubMed ID: 19671826 [No Abstract] [Full Text] [Related]
18. New treatments in scleroderma: the rheumatologic perspective. Righi A; Cerinic MM J Eur Acad Dermatol Venereol; 2002 Sep; 16(5):431-2. PubMed ID: 12428830 [No Abstract] [Full Text] [Related]
19. The role of DMARDs in systemic sclerosis therapy. Blank N; Max R; Lorenz HM Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii42-4. PubMed ID: 16987834 [TBL] [Abstract][Full Text] [Related]
20. Effect of the 34C>T variant in the AMPD1 gene on the clinical response to methotrexate in patients with rheumatoid arthritis: comment on the article by Wessels et al. Riksen NP; Rongen GA; Smits P; van Riel P; Barrera P Arthritis Rheum; 2007 Feb; 56(2):694; author reply 694-5. PubMed ID: 17265507 [No Abstract] [Full Text] [Related] [Next] [New Search]